TABLE 2.

Correlation of p16, ProExC, HPV DNA ISH and HPV DNA PCR with survival.

		OVERALL SURVIVAL		CANCER SPECIFIC SURVIVAL		TIME TO DISTANT METASTASIS
		HR	P-Value	HR	P-Value	HR	P-Value
WHOLE SECTIONS	p16≥5%	0.17 (0.07–0.43)	<0.0001	0.24 (0.08–0.68)	0.005	0.29 (0.05–1.61)	0.14
	p16 ≥50%	0.18 (0.07–0.48)	0.0001	0.23 (0.07–0.72)	0.006	0.14 (0.02–1.21)	0.03
	p16 ≥80%	0.27 (0.12–0.59)	0.005	0.34 (0.13–0.90)	0.05	0.26 (0.05–1.28)	0.14
	ProExC >33%	0.68 (0.23–2.00)	0.5	0.38 (0.12–1.20)	0.13	0.89 (0.08–9.64)	0.92
	ProExC>66	0.57 (0.25–1.27)	0.17	0.33 (0.12–0.90)	0.03	0.12 (0.01–1.03)	0.03
	HPV ISH	0.37 (0.17–0.83)	0.013	0.40 (0.15–1.04)	0.06	0.26 (0.05–1.41)	0.1
TMA	p16 ≥5%	0.17 (0.07–0.41)	<0.0001	0.25 (0.09–0.73)	0.004	0.49 (0.09–2.69)	0.37
	p16≥50%	0.21 (0.09–0.47)	0.0002	0.28 (0.10–0.77)	0.01	0.32 (0.06–1.65)	0.16
	p16 ≥80%	0.31 (0.14–0.69)	0.009	0.44 (0.16–1.16)	0.11	0.47 (0.10–2.36)	0.38
	ProExC >33%	0.88 (0.33–2.36)	0.8	1.82 (0.45–7.29)	0.38	3.20 (0.29–35.69)	0.33
	ProExC>66	0.32 (0.13–0.80)	0.008	0.44 (0.16–1.26)	0.11	0.77 (0.14–4.27)	0.76
	HPV ISH	0.33 (0.13–0.84)	0.01	0.45 (0.16–1.30)	0.13	0.49 (0.09–2.70)	0.4
PCR	HPV.PCR	0.72 (0.38–1.38)	0.32	0.42 (0.18–0.98)	0.04	0.08 (0.01–0.65)	0.003
	HPV PCR+ISH	0.19 (0.08–0.48)	<0.0001	0.18 (0.06–0.60)	0.0003	0.19 (0.03–1.14)	0.03

HR hazard ratio; ISH in situ hybridization; TMA tissue microarray